[1] CHATURVEDI SK, DESAI G. Measurement and assessment of somatic symptoms[J]. Int Review Psychiatry, 2013, 25(1): 31. doi: 10.3109/09540261.2012.727787
[2] BARSKY AJ, ORAV EJ, BATES DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity[J]. Arch Gen Psychiatry, 2005, 62(8): 903. doi: 10.1001/archpsyc.62.8.903
[3] GRÖNROS J, HAEGERMARK NILSSON E, KÖTELES F, et al. Association between somatic symptoms and modern health worries[J]. J Psychosom Res, 2020, 135: 110163. doi: 10.1016/j.jpsychores.2020.110163
[4] SIMON GE, VONKORFF M, PICCINELLI M, et al. An international study of the relation between somatic symptoms and depression[J]. New Engl J Med, 1999, 341(18): 1329. doi: 10.1056/NEJM199910283411801
[5] SAMBUCINI D, ACETO P, BEGOTARAJ E, et al. Efficacy of psychological interventions on depression anxiety and somatization in migrants: a meta-analysis[J]. J Immigr Minor Health, 2020, 22(6): 1320. doi: 10.1007/s10903-020-01055-w
[6] THAPAR A, COLLISHAW S, PINE DS, et al. Depression in adolescence[J]. Lancet (London, England), 2012, 379(9820): 1056. doi: 10.1016/S0140-6736(11)60871-4
[7] CERUTTI R, SPENSIERI V, PRESAGHI F, et al. Alexithymic traits and somatic symptoms in children and adolescents: a screening approach to explore the mediation role of depression[J]. Psychiatr Q, 2020, 91(2): 521. doi: 10.1007/s11126-020-09715-8
[8] KINNUNEN P, LAUKKANEN E, KYLMÄ J. Associations between psychosomatic symptoms in adolescence and mental health symptoms in early adulthood[J]. Int J Nursing Pract, 2010, 16(1): 43. doi: 10.1111/j.1440-172X.2009.01782.x
[9] RUSH AJ, TRIVEDI MH, WISNIEWSKI SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report[J]. Am J Psychiatr, 2006, 163(11): 1905. doi: 10.1176/ajp.2006.163.11.1905
[10] DREVETS WC, WITTENBERG GM, BULLMORE ET, et al. Immune targets for therapeutic development in depression: towards precision medicine[J]. Nat Rev Drug Discov, 2022, 21(3): 224. doi: 10.1038/s41573-021-00368-1
[11] WANG H, LI P, ZHANG Y, et al. Cytokine changes in different types of depression: specific or general[J]. Neurol Psychiatry Brain Res, 2020, 36: 39. doi: 10.1016/j.npbr.2020.02.009
[12] RIEF W, HENNINGS A, RIEMER S, et al. Psychobiological differences between depression and somatization[J]. J Psychosomatic Res, 2010, 68(5): 495. doi: 10.1016/j.jpsychores.2010.02.001
[13] 范肖冬. ICD-10精神与行为障碍分类: ICD-10精神与行为障碍分类[M]. 北京: 人民卫生出版社, 1993.
[14] 张园园, 刘果, 黄俊峰, 等. 儿童躯体化量表中文版的修订及信效度检验[J]. 国际精神病学杂志, 2015, 42(4): 4.
[15] 张作记. 行为医学量表手册: 行为医学量表手册[M]. 北京: 中华医学电子音像出版社, 2005.
[16] TALAROWSKA M, SZEMRAJ J, GAŁECKI P. The role of interleukin genes in the course of depression[J]. Open Med (Wars), 2016, 11(1): 41. doi: 10.1515/med-2016-0009
[17] BVAB C, MGMA B, SC A, et al. Higher Interleukin 13 differentiates patients with a positive history of suicide attempts in major depressive disorder[J]. J Affect Disord Rep, 2021, 6: 100254. doi: 10.1016/j.jadr.2021.100254
[18] 施蕾, 郑瑀, 许琳洁, 等. 抑郁症与白介素关系的研究进展[J]. 国际精神病学杂志, 2021, 48(1): 4.
[19] SOCZYNSKA JK, KENNEDY SH, ALSUWAIDAN M, et al. A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar Ⅰ/Ⅱ depression[J]. Bipolar Disord, 2017, 19(3): 198. doi: 10.1111/bdi.12496
[20] LUCEY DR, CLERICI M, SHEARER GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases[J]. Clin Microbiol Rev, 1996, 9(4): 532. doi: 10.1128/CMR.9.4.532
[21] KENIS G, MAES M. Effects of antidepressants on the production of cytokines[J]. Int J Neuropsychopharmacol, 2002, 5(4): 401. doi: 10.1017/S1461145702003164
[22] 汪崇泽, 盛国红. 免疫炎症途径与抑郁症的研究进展[J]. 精神医学杂志, 2015, 28(5): 397. doi: 10.3969/j.issn.2095-9346.2015.05.025